...
首页> 外文期刊>Biology of Sex Differences >Impact of sex and gender on COVID-19 outcomes in Europe
【24h】

Impact of sex and gender on COVID-19 outcomes in Europe

机译:性别和性别对欧洲Covid-19成果的影响

获取原文

摘要

Emerging evidence from China suggests that coronavirus disease 2019 (COVID-19) is deadlier for infected men than women with a 2.8% fatality rate being reported in Chinese men versus 1.7% in women. Further, sex-disaggregated data for COVID-19 in several European countries show a similar number of cases between the sexes, but more severe outcomes in aged men. Case fatality is highest in men with pre-existing cardiovascular conditions. The mechanisms accounting for the reduced case fatality rate in women are currently unclear but may offer potential to develop novel risk stratification tools and therapeutic options for women and men. The present review summarizes latest clinical and epidemiological evidence for gender and sex differences in COVID-19 from Europe and China. We discuss potential sex-specific mechanisms modulating the course of disease, such as hormone-regulated expression of genes encoding for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) entry receptors angiotensin converting enzyme (ACE) 2 receptor and TMPRSS2 as well as sex hormone-driven innate and adaptive immune responses and immunoaging. Finally, we elucidate the impact of gender-specific lifestyle, health behavior, psychological stress, and socioeconomic conditions on COVID-19 and discuss sex specific aspects of antiviral therapies. The sex and gender disparities observed in COVID-19 vulnerability emphasize the need to better understand the impact of sex and gender on incidence and case fatality of the disease and to tailor treatment according to sex and gender. The ongoing and planned prophylactic and therapeutic treatment studies must include prospective sex- and gender-sensitive analyses.
机译:来自中国的新兴证据表明,冠状病毒疾病2019年(Covid-19)对于受感染的男性比女性在中国男性中报告的2.8%的妇女与女性患者的死亡率相比,对妇女的死亡率有死亡。此外,几个欧洲国家的Covid-19的性别分列数据显示了性别之间的案件数量,但老年人的成果更严重。具有预先存在的心血管条件的男性中病例最高。核对妇女案例减少死亡率的机制目前不明确,但可能提供促进妇女和男性的新风险分层工具和治疗选择的潜力。本综述总结了来自欧洲和中国的Covid-19性别和性别差异的最新临床和流行病学证据。我们讨论调节疾病疗程的潜在性特异性机制,例如对严重急性呼吸综合征冠状病毒2(SARS-COV2)入口受体血管紧张素转化酶(ACE)2受体和TMPRSS2以及TMPRSS2以及TMPRSS2以及TMPRSS2以及性激素驱动的先天和适应性免疫应答和免疫。最后,我们阐明了性别特异性生活方式,健康行为,心理压力和社会经济条件对Covid-19的影响,并讨论了抗病毒疗法的性别特定方面。在Covid-19漏洞中观察到的性别和性别差异强调需要更好地了解性别和性别对疾病发病率和病例的影响,并根据性别和性别定制治疗。正在进行的和计划的预防性和治疗性治疗研究必须包括前瞻性和性别敏感性分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号